| scholarly article | Q13442814 |
| P50 | author | Jan Delabie | Q28379730 |
| P2093 | author name string | A Tierens | |
| E Torlakovic | |||
| H D Dang | |||
| P2860 | cites work | Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications | Q24561689 |
| Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1 | Q24671782 | ||
| Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 | ||
| Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1 | Q28255383 | ||
| Characterization of EBV-genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma | Q28273953 | ||
| Oct-2, although not required for early B-cell development, is critical for later B-cell maturation and for postnatal survival | Q28513024 | ||
| An inhibitory carboxyl-terminal domain in Ets-1 and Ets-2 mediates differential binding of ETS family factors to promoter sequences of the mb-1 gene | Q28586875 | ||
| PU.1 is required for myeloid-derived but not lymphoid-derived dendritic cells | Q28592288 | ||
| The role of Ets family transcription factor PU.1 in hematopoietic cell differentiation, proliferation and apoptosis | Q33714980 | ||
| The transcription factor PU.1 does not regulate lineage commitment but has lineage-specific effects | Q33782018 | ||
| Characteristics of new cell lines derived from Burkitt lymphomas | Q34203709 | ||
| Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development | Q35888216 | ||
| PU.1 can participate in an active enhancer complex without its transcriptional activation domain | Q35902741 | ||
| Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities | Q35911056 | ||
| Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells | Q36565828 | ||
| Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice. | Q36771150 | ||
| PU.1 recruits a second nuclear factor to a site important for immunoglobulin kappa 3' enhancer activity | Q36809426 | ||
| Ets proteins: new factors that regulate immunoglobulin heavy-chain gene expression | Q36826409 | ||
| B cell development and immunoglobulin gene transcription in the absence of Oct-2 and OBF-1. | Q38302908 | ||
| Establishment of a malignant, epstein-barr-virus (EBV)-negative cell-line from the pleura effusion of a patient with Hodgkin's disease | Q40202979 | ||
| PU.1 is a component of a multiprotein complex which binds an essential site in the murine immunoglobulin lambda 2-4 enhancer | Q40656361 | ||
| A new B-cell line showing a complex translocation (8;14;18) and BCL2 rearrangement | Q40665976 | ||
| Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription | Q40832778 | ||
| PU.1 and hematopoiesis: lessons learned from gene targeting experiments | Q40856042 | ||
| Targeted disruption of the Oct-2 locus in a B cell provides genetic evidence for two distinct cell type-specific pathways of octamer element-mediated gene activation | Q40873369 | ||
| PU.1 expression in microglia | Q40894354 | ||
| Somatic mutations within the untranslated regions of rearranged Ig genes in a case of classical Hodgkin's disease as a potential cause for the absence of Ig in the lymphoma cells | Q40952533 | ||
| Overexpression of B cell-specific activator protein (BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation to an Ig high producer cell with plasma cell phenotype. | Q41119000 | ||
| Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator | Q41337122 | ||
| Transcription factors required for lymphoid lineage commitment | Q41429694 | ||
| Transcription factors, normal myeloid development, and leukemia | Q41534189 | ||
| Regulation of lymphoid-specific immunoglobulin mu heavy chain gene enhancer by ETS-domain proteins | Q41542622 | ||
| Role of PU.1 in hematopoiesis | Q41706344 | ||
| Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells | Q42755968 | ||
| Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines | Q42811736 | ||
| Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. | Q42819499 | ||
| Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. | Q42830367 | ||
| Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. | Q43962210 | ||
| Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles | Q44052164 | ||
| Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas | Q47725222 | ||
| Loss- and gain-of-function mutations reveal an important role of BSAP (Pax-5) at the start and end of B cell differentiation | Q47998067 | ||
| Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells | Q48046017 | ||
| Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes | Q48080289 | ||
| Expression of B cell-associated transcription factors in B-cell precursor acute lymphoblastic leukemia cells: association with PU.1 expression, phenotype, and immunogenotype. | Q52166674 | ||
| PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. | Q52192218 | ||
| The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines | Q52205709 | ||
| Biology of the human malignant lymphomas. I. Establishment in continuous cell culture and heterotransplantation of diffuse histiocytic lymphomas. | Q53436674 | ||
| Regulation of B lymphocyte and macrophage development by graded expression of PU.1. | Q55033922 | ||
| Ets-related protein PU.1 regulates expression of the immunoglobulin J-chain gene through a novel Ets-binding element | Q70495981 | ||
| Nodular lymphocyte predominance Hodgkin's disease. A distinct clinicopathological entity | Q72395727 | ||
| Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin | Q73168641 | ||
| Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription | Q73426936 | ||
| Clonality in nodular lymphocyte-predominant Hodgkin's disease | Q73572124 | ||
| Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin's disease | Q73664503 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lymphocyte | Q715347 |
| P304 | page(s) | 1807-1814 | |
| P577 | publication date | 2001-11-01 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease | |
| P478 | volume | 159 |
| Q53431646 | A Case of Chemotherapy-Refractory "THRLBCL like Transformation of NLPHL" Successfully Treated with Lenalidomide. |
| Q80347643 | Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma |
| Q29622911 | BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas |
| Q41969041 | Bob-1 is expressed in classic Hodgkin lymphoma |
| Q30653046 | CluGene: A Bioinformatics Framework for the Identification of Co-Localized, Co-Expressed and Co-Regulated Genes Aimed at the Investigation of Transcriptional Regulatory Networks from High-Throughput Expression Data |
| Q37016499 | Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. |
| Q38596350 | Contribution of the Epstein-Barr Virus to the Pathogenesis of Hodgkin Lymphoma |
| Q35013338 | Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification |
| Q40669895 | Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines |
| Q34549468 | EBV in Hodgkin Lymphoma |
| Q36513571 | Epidemiology and pathologic features of Hodgkin lymphoma |
| Q39441384 | Epigenetic and transcriptional control of the 15-lipoxygenase-1 gene in a Hodgkin lymphoma cell line. |
| Q26998999 | Epstein-Barr virus and the origin of Hodgkin lymphoma |
| Q41921960 | Expression of B-lymphocyte-associated transcription factors in human T-cell neoplasms |
| Q24675877 | Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas |
| Q83223363 | Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays |
| Q43872764 | Heterogeneous expression of Src tyrosine kinases Lyn, Fyn and Syk in classical Hodgkin lymphoma: prognostic implications |
| Q34643277 | Hodgkin lymphoma |
| Q33588862 | Hodgkin lymphoma: an update on its biology with new insights into classification |
| Q34564836 | Hodgkin's lymphoma: the pathologist's viewpoint |
| Q60345402 | Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas |
| Q48036231 | Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples |
| Q37738584 | Is Hodgkin lymphoma just another B-cell lymphoma? |
| Q42854935 | Loss of Expression of the WNT/β-Catenin-Signaling Pathway Transcription Factors Lymphoid Enhancer Factor-1 (LEF-1) and T Cell Factor-1 (TCF-1) in a Subset of Peripheral T Cell Lymphomas |
| Q38164572 | Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin. |
| Q40864458 | Mediastinal Gray Zone Lymphoma: A Wider Category Than We Think? |
| Q40796275 | Nodular lymphocyte-predominant hodgkin lymphoma or T-cell/histiocyte rich large B-cell lymphoma: the problem in "grey zone" lymphomas. |
| Q35618780 | Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells |
| Q33557469 | Quantifying deleterious effects of regulatory variants |
| Q37004635 | Recent insights into the biology of Hodgkin lymphoma: unraveling the mysteries of the Reed-Sternberg cell |
| Q36206169 | Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma |
| Q37955807 | T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification |
| Q42879198 | T-cell/histiocyte-rich large B-cell lymphoma |
| Q79276796 | The B-Cell Transcription Factors BSAP, Oct-2, and BOB.1 and the Pan-B-Cell Markers CD20, CD22, and CD79a Are Useful in the Differential Diagnosis of Classic Hodgkin Lymphoma |
| Q37349652 | The biology of Hodgkin's lymphoma |
| Q58099160 | The c-Jun and JunB transcription factors facilitate the transit of classical Hodgkin lymphoma tumour cells through G |
| Q40493273 | The early transcription factor GATA-2 is expressed in classical Hodgkin's lymphoma |
| Q53367286 | [Nodular lymphocyte predominance Hodgkin's disease and its differential diagnosis]. |
Search more.